Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
Chromosomal microarray (CMA) testing may be considered medically necessary as first-line testing in the initial evaluation of individuals with apparent nonsyndromic developmental delay or intellectual disability, autism spectrum disorder, or multiple congenital anomalies not specific to a well-delineated genetic syndrome. CMA is considered investigational for all other conditions of delayed development, including idiopathic growth or language delay. Panel testing using next-generation sequencing is considered investigational in all cases of suspected genetic abnormality in children with developmental delay or intellectual disability, autism spectrum disorder, or congenital anomalies, and CMA testing is not intended for use in the prenatal period.